CONNEQT Health Surpasses $7M Pulse Revenue Run-Rate Despite Supply Hurdles

Pulse Sales Scale Despite Supply Constraints

CONNEQT Health (ASX:CQT) recorded a notable milestone in the March quarter, pushing its CONNEQT Pulse device sales to an annualised revenue run-rate of around A$7 million. This growth came despite a temporary supply bottleneck affecting large cuffs, which historically make up about 70% of sales, causing a sales slowdown in February. The supply issue was resolved during the quarter, allowing the company to resume growth momentum and exit the period at a higher run-rate.

The ability to deliver sequential growth amid product shortages suggests robust underlying consumer demand and effective marketing strategies. The company’s revised pricing model, introduced in the December 2025 quarter, continues to strike a balance between accessibility and margin, supported by expanding subscription offerings such as Care+ and in-app purchases, which saw a 51% quarter-on-quarter revenue increase. This consumer traction complements the growing enterprise channel, which onboarded 10 clinical sites during the quarter, advancing CONNEQT’s shift towards recurring, usage-based revenue streams.

Marketing efforts have been bolstered by third-party validation, with the CONNEQT Pulse recognised by AARP as one of the “Best Blood Pressure Monitors of 2026” and awarded for “Most Comprehensive Data.” This endorsement is expected to enhance brand credibility among at-risk demographics and support organic demand. The company has also leveraged user-generated content and customer reviews to improve conversion efficiency and customer lifetime value, moving beyond awareness to deeper engagement.

Enterprise Channel Expansion and Platform Development

CONNEQT’s enterprise strategy gained traction with the addition of eight new clinical accounts, bringing total active enterprise subscriptions to 10. These sites are early adopters of the company’s usage-based arterial health assessment model, primarily targeting performance testing labs and concierge clinical practices. This model replaces one-time capital equipment sales with a combination of deployment fees, subscriptions, and utilisation-based revenue, aiming to embed assessments into routine workflows and create scalable recurring income.

On the technology front, the company continued enhancing its Arterial Intelligence™ platform, decoupling core algorithms from hardware to enable cloud-based deployment across devices and applications. Upcoming updates to the CONNEQT app are designed to boost consumer engagement and lay the groundwork for expanded subscription features and add-on services, positioning the company to broaden its vascular biomarker offerings in FY27 and beyond.

Cash Flow Pressures and Funding Initiatives

Financially, CONNEQT reported a net cash outflow from operating activities of A$2.967 million for the quarter, with cash and cash equivalents declining to A$456,000. This outflow reflects ongoing investments in marketing, staff, and product manufacturing, although product manufacturing costs decreased compared to the prior quarter. Advertising spend, primarily for customer acquisition, also eased slightly.

To support its growth trajectory, the company secured a new A$1.115 million R&D loan facility post-quarter, structured around the expected R&D Tax Incentive Refund for FY2026. Additionally, related party C2 Ventures provided a further unsecured loan of A$950,000 during the quarter, with shareholder approval granted for converting prior loans into convertible notes and shares. Despite a tight cash runway estimated at approximately 0.15 quarters based on current operating cash flows, management anticipates that growing revenues from consumer sales, subscriptions, and enterprise contracts, alongside further capital raises underway, will sustain operations.

CONNEQT’s financial position and growth plans echo its recent strategic moves, including a $3.1 million capital raise in December 2025 and a pivot towards recurring revenue models. The company’s ability to navigate supply chain challenges and ramp up both consumer and enterprise channels will be critical as it seeks to extend its market footprint and improve cash flow dynamics.

With the March quarter behind it, CONNEQT is poised to capitalise on normalised supply and sustained demand, focusing on scaling Pulse sales, expanding subscription revenue, and deepening enterprise utilisation. The company’s upcoming investor webinar on 1 May 2026 will likely shed more light on these initiatives and the path ahead.

Given the company’s ongoing cash burn and reliance on external funding, the coming quarters will test CONNEQT’s execution and capital management discipline as it pursues its vision of a scalable, data-driven vascular health platform.

This progress builds on earlier momentum, including the company’s reported 40% revenue growth in the half-year to December 2025 and over 200% Pulse sales surge in prior quarters, underscoring a consistent trajectory of commercial expansion and strategic transformation Pulse sales soar 200 percent Accelerates revenue growth.